Company intelligence / Profile preview
Aravive, Inc.
- Ownership
- Public · ARAV
- Development stage
- Other
Overview
Aravive was a clinical-stage biopharmaceutical company focused on developing transformative treatments for life-threatening diseases such as cancer and fibrosis. Its lead candidate, batiraxcept (AVB-S6/S6–500), an ultrahigh-affinity decoy protein targeting the GAS6/AXL pathway, reached Phase III trials in platinum-resistant recurrent ovarian cancer but failed to show efficacy over standard of care. Other programs included early-phase studies in clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company has faced significant setbacks following the failure of its pivotal trial and has limited cash runway[7][9].
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Recombinant fusion proteins (decoy proteins)Monoclonal antibodies (in partnership/licensing context)Antibody fusion proteins
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Aravive, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aravive, Inc..